1. Home
  2. ESRT vs GERN Comparison

ESRT vs GERN Comparison

Compare ESRT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empire State Realty Trust Inc.

ESRT

Empire State Realty Trust Inc.

HOLD

Current Price

$5.44

Market Cap

907.0M

Sector

Real Estate

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.15

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESRT
GERN
Founded
2011
1990
Country
United States
United States
Employees
N/A
258
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
907.0M
808.3M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
ESRT
GERN
Price
$5.44
$1.15
Analyst Decision
Hold
Hold
Analyst Count
3
3
Target Price
$6.35
$2.17
AVG Volume (30 Days)
2.1M
11.6M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$768,270,000.00
N/A
Revenue This Year
$4.26
$26.91
Revenue Next Year
$1.52
$43.75
P/E Ratio
$540.00
N/A
Revenue Growth
0.05
N/A
52 Week Low
$4.87
$1.04
52 Week High
$8.76
$2.01

Technical Indicators

Market Signals
Indicator
ESRT
GERN
Relative Strength Index (RSI) 46.70 34.14
Support Level $5.29 $1.05
Resistance Level $5.83 $1.30
Average True Range (ATR) 0.19 0.06
MACD -0.02 0.00
Stochastic Oscillator 31.54 27.08

Price Performance

Historical Comparison
ESRT
GERN

About ESRT Empire State Realty Trust Inc.

Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: